Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus Macaques

25 Mar 2015

Abstract excerpt

Oncolytic viruses (OVs) have shown promising clinical activity when administered by direct intratumoral injection. However, natural barriers in the blood, including antibodies and complement, are likely to limit the ability to repeatedly administer OVs by the intravenous route. We demonstrate here that for a prototype of the clinical vaccinia virus based product Pexa-Vec, the neutralizing activity of antibodies...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Herpesvirus Infections and Treatments
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25807289
DOI: 10.1038/mt.2015.49

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus MacaquesPMID 25807289Read ↗

Variola virus immune evasion design: Expression of a highly efficient inhibitor of human complementSemantic proximity Read ↗

Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.Semantic proximity Read ↗

Inhibition of the Complement Cascade by the Major Secretory Protein of Vaccinia VirusSemantic proximity Read ↗

A rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis.Semantic proximity Read ↗

Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelopeSemantic proximity Read ↗

Complement C4 Prevents Viral Infection through Capsid InactivationSemantic proximity Read ↗

Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo.Semantic proximity Read ↗

Complement Protein C1q Inhibits Antibody-Dependent Enhancement of Flavivirus Infection in an IgG Subclass-Specific MannerSemantic proximity Read ↗

Identification of complement regulatory domains in vaccinia virus complement control protein.Semantic proximity Read ↗

Incorporation of Host Complement Regulatory Proteins into Newcastle Disease Virus Enhances Complement EvasionSemantic proximity Read ↗

Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo.Semantic proximity Read ↗

Intravenous and isolated limb perfusion delivery of wild type and a tumor-selective replicating mutant vaccinia virus in nonhuman primates.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.